TheStreet lowered shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a c- rating to a d rating in a report issued on Friday.
Several other analysts have also recently weighed in on the company. Zacks Investment Research cut Syndax Pharmaceuticals from a hold rating to a sell rating in a report on Friday, January 5th. B. Riley reissued a buy rating and set a $40.00 price objective on shares of Syndax Pharmaceuticals in a report on Thursday, January 18th. Morgan Stanley dropped their price objective on Syndax Pharmaceuticals from $25.00 to $24.00 and set an overweight rating for the company in a report on Wednesday, March 14th. ValuEngine raised Syndax Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, March 20th. Finally, BidaskClub raised Syndax Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. Syndax Pharmaceuticals currently has an average rating of Buy and a consensus target price of $23.86.
Syndax Pharmaceuticals stock opened at $10.76 on Friday. The stock has a market capitalization of $282.05, a P/E ratio of -3.71 and a beta of 1.04. Syndax Pharmaceuticals has a 12-month low of $7.41 and a 12-month high of $15.43.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Monday, March 5th. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.04). The firm had revenue of $1.19 million for the quarter, compared to the consensus estimate of $0.75 million. Syndax Pharmaceuticals had a negative return on equity of 63.51% and a negative net margin of 2,884.34%. Syndax Pharmaceuticals’s quarterly revenue was up 290.2% on a year-over-year basis. research analysts predict that Syndax Pharmaceuticals will post -3.52 EPS for the current fiscal year.
In other news, insider Peter Ordentlich sold 7,500 shares of the business’s stock in a transaction dated Tuesday, April 3rd. The stock was sold at an average price of $15.00, for a total transaction of $112,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 24.10% of the stock is currently owned by insiders.
Several institutional investors have recently bought and sold shares of the company. BVF Inc. IL acquired a new position in shares of Syndax Pharmaceuticals during the 4th quarter worth about $28,326,000. Millennium Management LLC grew its position in shares of Syndax Pharmaceuticals by 18.9% during the 4th quarter. Millennium Management LLC now owns 516,500 shares of the company’s stock worth $4,525,000 after buying an additional 82,256 shares during the period. Geode Capital Management LLC grew its position in shares of Syndax Pharmaceuticals by 17.4% during the 4th quarter. Geode Capital Management LLC now owns 153,483 shares of the company’s stock worth $1,344,000 after buying an additional 22,803 shares during the period. Crestline Management LP grew its position in shares of Syndax Pharmaceuticals by 55.3% during the 4th quarter. Crestline Management LP now owns 83,139 shares of the company’s stock worth $728,000 after buying an additional 29,607 shares during the period. Finally, State Street Corp grew its position in shares of Syndax Pharmaceuticals by 32.8% during the 2nd quarter. State Street Corp now owns 81,327 shares of the company’s stock worth $1,137,000 after buying an additional 20,106 shares during the period. Institutional investors own 69.55% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Syndax Pharmaceuticals (SNDX) Rating Lowered to D at TheStreet” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at www.tickerreport.com/banking-finance/3364448/syndax-pharmaceuticals-sndx-rating-lowered-to-d-at-thestreet.html.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Companys product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.